Article
Complex Dynamics in the Heart Failure Market: Balancing Treatment Strategies and Loss of Protection Events
IQVIA Forecast Link
Jun 16, 2023

Heart failure is a debilitating medical condition characterized by impaired cardiac function, resulting in inadequate blood circulation and a myriad of symptoms including dyspnea, fatigue, edema, and palpitations. According to IQVIA's Patient Link, it had a total disease population of over 54 million in 2022 and thus poses a substantial burden on both individuals and healthcare systems worldwide.

The etiology of heart failure encompasses a range of factors, including coronary artery disease, hypertension, cardiomyopathy, heart valve disorders, congenital anomalies, and myocardial infarction. These underlying causes contribute to the development of systolic and diastolic dysfunction, the two primary pathophysiological mechanisms in heart failure.

Systolic dysfunction manifests as reduced contractility and diminished ejection fraction, impairing the heart's pumping efficiency. Diastolic dysfunction, on the other hand, arises from impaired ventricular relaxation and filling, leading to elevated filling pressures. Both types may coexist or transition over time based on the individual's condition and disease progression.

Heart failure causes a substantial toll on healthcare systems, necessitating extensive medical interventions, frequent hospitalizations, and significant financial resources. As a leading cause of hospitalization and mortality, it warrants attention from pharmaceutical and medical device companies. Advancements in treatment modalities, including drug therapies, implantable devices, and cardiac rehabilitation programs, are pivotal in managing heart failure and improving patient outcomes.

To read more, please fill in your details on the left to download the article.

Related solutions

Contact Us